SLC5A2 and hydrops fetalis: The absence of a significant benefit of the combination of SGLT2‐I and RAAS‐Is on both composite cardiovascular outcome and composite outcome of cardiovascular death or HF hospitalization leaves room for the use of only SGLT2‐Is in populations that may be struggling with polypharmacy and de‐prescribing of some agents necessary.